National research network Canadian Cancer Trials Group (CCTG) has obtained a grant of $30m from the Canadian Cancer Society (CCS) to guarantee continued access to impactful clinical trials.
The latest five-year funding is a renewal of CCS’ support of CCTG.
The process of renewal comprises a thorough review including a complete grant submission and site visit with external reviewers who examine all the elements of the CCTG’s work and its effect on clinical trials research.
CCS Mission, Research & Advocacy executive vice-president Dr Stuart Edmonds said: “CCS is proud to continue to provide core funding for CCTG, and we’re incredibly grateful to our donors who make this support possible.
“With an international reputation for running Canada’s most impactful cancer clinical trials, CCTG’s work benefits not just people with cancer in Canada but around the world.”
The latest funds will aid CCTG in supporting its key goals as well as the development and execution of trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Boosting cancer outcomes in collaboration with patients is a key part of the research initiatives of CCTG.
The group’s Patient Representative Committee guarantees that the requirements and priorities of the patients are taken into account in all trial designs and works.
CCTG director Dr Janet Dancey said: “The successful CCS grant renewal is a recognition of the exceptional calibre of our national scientific leaders, international research activities and the impact our trials have on new treatments for people with cancer.
“The funding will ensure that Canadian led trials find answers to what is most important to Canadian patients and clinicians.”